4sCAR-DLL3 CAR-T Therapy (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2025/09/23 20:00:05

Base Information

Drug Name4sCAR-DLL3 CAR-T Therapy (Shenzhen Geno-Immune Medical Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionT lymphocyte replacements

TargetsDelta-like protein 3

Therapy Area/IndicationsMelanomaGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesShenzhen Geno-Immune Medical Institute

China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Geno-Immune Medical Institute

Inactive CompaniesN/A

Active IndicationsMelanomaGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A